Hyperhidrosis treatment with bornaprine in the acute phase of spinal cord-injured patients
Related Experiment Video
Updated: Jul 6, 2026
Breathing-controlled Electrical Stimulation (BreEStim) for Management of Neuropathic Pain and Spasticity
Published on: January 10, 2013
R Sergi1, A Massone, S Moretto
1Department of Rehabilitation, Spinal Cord Injury Unit, Santa Corona Hospital, Pietra Ligure, Savona, Italy. roberto.sergi@ospedalesantacorona.it
Study Design:
Original article.
Objective:
To test the use of bornaprine in the hyperhidrosis treatment in the acute phase of spinal cord-injured patients.
Setting:
Patients with acute spinal cord lesions in the Spinal Unit of Pietra Ligure, Savona, Italy.
Method:
In 4 years, 12 patients have been treated, for a maximum period of 75 days, with dosages ranging from 2 to 4 mg day(-1).
Results:
All of them reported long-lasting subjective benefits, without side effects, even after the interruption of the therapy.
Conclusion:
The bornaprine treatment, at 2 or 4 mg day(-1) dosage, has been effective and safe to contrast hyperhidrosis, in the acute phase of spinal cord-injured patients. This positive experience would require additional trials and a larger number of cases to gain a more solid support.
Related Concept Videos
01:29Decreased Body Temperature
01:26Peripheral Artery Disease IV: Nursing Management